Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: 5. Diagnostic tools for early detection.

Literature DB >> 9835884

Prostate cancer: 5. Diagnostic tools for early detection.

P I Karakiewicz¹, A G Aprikian.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1998 PMID： 9835884 PMCID： PMC1229783

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

37 in total

1. To color Doppler image the prostate or not: that is the question.

Authors: A A Alexander
Journal: Radiology Date: 1995-04 Impact factor: 11.105

2. Outcome of sextant biopsy according to gland volume.

Authors: P I Karakiewicz; M Bazinet; A G Aprikian; C Trudel; S Aronson; M Nachabé; F Péloquint; J Dessureault; M S Goyal; L R Bégin; M M Elhilali
Journal: Urology Date: 1997-01 Impact factor: 2.649

Review 3. Making the most out of six systematic sextant biopsies.

Authors: T A Stamey
Journal: Urology Date: 1995-01 Impact factor: 2.649

4. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Authors: S L Goldenberg; L H Klotz; J Srigley; M A Jewett; D Mador; Y Fradet; J Barkin; J Chin; J M Paquin; M J Bullock; S Laplante
Journal: J Urol Date: 1996-09 Impact factor: 7.450

5. Family history and the risk of prostatic carcinoma in a high risk group of urological patients.

Authors: A G Aprikian; M Bazinet; M Plante; A Meshref; C Trudel; S Aronson; M Nachabe; F Péloquin; J Déssureault; S Narod
Journal: J Urol Date: 1995-08 Impact factor: 7.450

6. Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

Authors: M K Brawer; J Beatie; M H Wener; R L Vessella; S D Preston; P H Lange
Journal: J Urol Date: 1993-07 Impact factor: 7.450

7. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors: M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal: J Urol Date: 1992-03 Impact factor: 7.450

8. Analysis of gland volume effect on the performance of PSA density in early detection of non-palpable, isoechoic prostate cancer.

Authors: Pierre I. Karakiewicz; Michel Bazinet; Armen G. Aprikian; Claude Trudel; Samual Aronson; Francois Péloquin; Jean Dessureault; Mahmoud Nachabé; Michelle S. Goyal; Louis R. Bégin; Mostafa M. Elhilali
Journal: Can J Urol Date: 1996-06 Impact factor: 1.344

Prostate cancer: 5. Diagnostic tools for early detection.

1. To color Doppler image the prostate or not: that is the question.

2. Outcome of sextant biopsy according to gland volume.

Review 3. Making the most out of six systematic sextant biopsies.

4. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

5. Family history and the risk of prostatic carcinoma in a high risk group of urological patients.

6. Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

7. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

8. Analysis of gland volume effect on the performance of PSA density in early detection of non-palpable, isoechoic prostate cancer.

Review 9. Screening, early detection, and treatment of prostate cancer: a European view.

10. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

1. Prostate cancer from a patient's perspective.

2. Understanding obesity.

3. The more the better?

4. Understanding obesity.

5. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.